Glucagon-like peptide-1 receptor agonists are pivotal in managing T2DM and obesity, enhancing glycaemic control by boosting insulin secretion, reducing glucagon levels, delaying gastric emptying, and promoting satiety. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.